Clinical trials: Mask
Neurotrophic Keratopathy
Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy
The objective of this study is to evaluate the safety and effectiveness of OC-01 (varenicline) nasal spray as compared to placebo nasal spray for mean change from baseline in corneal fluorescein staining in subjects with Stage 1…
- Trial name
- NCT04957758
- Testing
- OC-01 (varenicline) nasal spray 1.2 mg/ml
- Where
- 31 sites in United States
- Volunteers
- 113 people
- Sponsor
- Oyster Point Pharma, Inc.
Neovascular (Wet) Age-Related Macular Degeneration
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
The primary objectives of the study are to determine the safety of high-dose aflibercept (hereafter referred to as HD) and to determine if HD provides greater intraocular pharmacodynamic (PD) effect and/or longer duration of…
- Trial name
- CANDELA (NCT04126317)
- Testing
- aflibercept, High-dose aflibercept
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 106 people
- Sponsor
- Regeneron Pharmaceuticals
Allergic Rhinitis, Allergic Conjunctivitis
An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo
The purpose of this study is to evaluate the onset of action of fluticasone propionate nasal spray compared to placebo nasal spray in reducing nasal allergic signs and symptoms following ragweed exposure in the Allergen BioCube…
- Trial name
- NCT01439815
- Testing
- Fluticasone Propionate Nasal Spray, Saline Nasal Spray
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- ORA, Inc.
Ocular Hypertension, Open-angle Glaucoma
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution
- Trial name
- NCT02207621
- Testing
- AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02% BID
- Where
- United States
- Volunteers
- 756 people
- Sponsor
- Aerie Pharmaceuticals
Blepharitis
Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to vehicle (placebo) in subjects with signs and symptoms of inflammatory meibomian gland disease.
- Trial name
- Maui (NCT02218489)
- Testing
- KPI-121, Vehicle
- Where
- 8 sites in United States
- Volunteers
- 206 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Mydriasis, Dilation
Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis
The objectives of this study are: To evaluate the efficacy of Nyxol (phentolamine mesylate ophthalmic solution 1%) to expedite the reversal of pharmacologic mydriasis To evaluate the safety of Nyxol To evaluate the effect of…
- Trial name
- NCT04024891
- Testing
- Phentolamine Mesylate Ophthalmic Solution 1%
- Where
- 4 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Age Related Macular Degeneration
The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot
Treatment of exudative age-related macular degeneration has been significantly improved by the advent of Lucentis™( which provides improved vision rather than simply stabilization) is common; however, monthly injections may be…
- Trial name
- MAP (NCT00605423)
- Testing
- Fluocinolone Acetonide/Medidur
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Johns Hopkins University
Allergic Conjunctivitis
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- NCT01881113
- Testing
- AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aciex Therapeutics, Inc.
Dry Eye Disease
Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients
The purpose of this study was to determine if difluprednate ophthalmic emulsion is effective in reducing the ocular symptoms of dry eye disease, as measured by a global Visual Analog Scale (VAS) discomfort score.
- Trial name
- NCT01276223
- Testing
- Difluprednate 0.05% ophthalmic emulsion, Difluprednate vehicle
- Where
- United States
- Volunteers
- 722 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and…
- Trial name
- NCT02089113
- Testing
- Dexamethasone
- Volunteers
- 241 people
- Sponsor
- Ocular Therapeutix, Inc.
Diabetic Macular Edema, Visual Impairment
A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
Study of efficacy and safety of 0.5 mg ranibizumab in Chinese patients with diabetic macular edema (DME)
- Trial name
- REFINE (NCT02259088)
- Testing
- Ranibizumab (RFB002), Laser
- Where
- 28 sites in China
- Volunteers
- 384 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Disease
Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)
The objective of this study is to evaluate the safety and effectiveness of OC-02 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.
- Trial name
- NCT03452397
- Testing
- 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL), 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL), 2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
- Where
- 3 sites in United States
- Volunteers
- 165 people
- Sponsor
- Oyster Point Pharma, Inc.
Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with…
- Trial name
- HAWK (NCT02307682)
- Testing
- Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
- Where
- United States
- Volunteers
- 1,775 people
- Sponsor
- Alcon Research
Presbyopia
A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia
This is a safety, efficacy and pharmacokinetics study of the fixed combination of AGN-199201 and AGN-190584 in participants with presbyopia (inability to focus on items close-up).
- Trial name
- NCT02780115
- Testing
- AGN-199201 ophthalmic solution, AGN-190584 ophthalmic solution, AGN-199201 Vehicle
- Where
- 25 sites in United States
- Volunteers
- 151 people
- Sponsor
- Allergan
Diabetic Retinopathy
Nesvategrast (OTT166) in Diabetic Retinopathy (DR)
This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.
- Trial name
- NCT05409235
- Testing
- OTT166, Vehicle control
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 225 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Ocular Hypertension, Open-Angle Glaucoma
A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma
The purpose of this study is to determine if the clinical profile of topical-ocular MGV354 merits further development for the indication of lowering intraocular pressure (IOP).
- Trial name
- NCT02743780
- Testing
- MGV354 ophthalmic suspension
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Treatment Resistant Depression
BPL-003 Efficacy and Safety in Treatment Resistant Depression
This is a Phase 2 study randomized, quadruple-masked, multi-center trial with an open-label extension (OLE), designed to investigate the efficacy and safety of BPL-003 in patients with treatment resistant depression (TRD).
- Trial name
- NCT05870540
- Testing
- BPL-003
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 196 people
- Sponsor
- Beckley Psytech Limited
Retinopathy of Prematurity
Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity
Retinopathy of prematurity (ROP) is a blinding disease affecting infants born prematurely. These infants do not have enough essential fatty acids to structurally support the retina, the nerve tissue in the eye which allows us to…
- Trial name
- NCT02486042
- Testing
- Omegaven, Standard lipids (primarily omega-6 fatty acids)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of California, San Diego
Macular Edema, Diabetic
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
The study hypothesis under test is that administration of the CCR2/5 antagonist has the potential to be as effective as the current treatment options for subjects with diabetic macular edema.
- Trial name
- NCT01994291
- Testing
- Ranibizumab, PF-04634817
- Where
- 63 sites in United States, Bulgaria and 7 more
- Volunteers
- 199 people
- Sponsor
- Pfizer
OSA
Nasal Pillows vs. Nasal Masks at High CPAP Pressure
The aim of this evaluation is to test: 1. Whether using nasal pillows at high pressures has comparable outcomes to nasal masks 2. Patient mask type preferences at high pressures
- Trial name
- NCT01690923
- Testing
- Nasal mask, Pillows mask
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- ResMed